Feb. 11—Another local medical provider is offering an intravenous antibody therapy that may help COVID-19 patients avoid hospital stays and recover more quickly with fewer complications.
The Wright Center for Community Health is now operating a Scranton outpatient infusion clinic administering the monoclonal antibody bamlanivimab, which received emergency use authorization as a COVID-19 treatment in November.
“Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens like viruses,” according to the U.S. Food and Drug Administration. Developed by the pharmaceutical firm Eli Lilly and Co., bamlanivimab is a monoclonal antibody specifically directed against the spike protein of SARS-CoV-2, the virus that causes COVID-19. It’s “designed to block the virus’ attachment and entry into human cells,” according to the FDA.
“We know what kind of neutralizing antibodies our body makes, either when we get an infection or when we get a vaccine,” said Dr. Jignesh